Skip to main content

Table 1 Clinical data of five LHON patients at baseline and exit examinations during the cyclosporine trial

From: Cyclosporine A does not prevent second-eye involvement in Leber’s hereditary optic neuropathy

Patient Age Gender mtDNA mutation Heteroplasmy level (%) Baseline Visual function
First eye
Baseline visual function
Second eye
Time between initial visual loss and beginning of treatment (weeks) Time between beginning of treatment and second eye visual loss (weeks) Time between involvement of the two eyes (weeks) Exit Visual Function
First Eye
Exit Visual Function
Second Eye
Visual acuity (logMar) [Snellen] Visual field (MD) Visual acuity (logMar) [Snellen] Visual field (MD) Visual acuity (logMar) [Snellen] Visual field (MD) Visual acuity (logMAr) [Snellen] Visual field (MD)
1 42 F 11778 98.17 0.8 [20/125] −1.24 0
[20/20]
0.65 16 15 31 2.1
[HM]
−32.55 2.1
[HM]
−32.08
2 30 M 11778 100 0.5
[20/63]
−2.89 0
[20/20]
−1.88 17 11 28 1.6
[20/800]
−22.85 1.1
[20/250]
−12.41
3 26 M 11778 98 1.1
[20/250]
−7.81 0
[20/20]
−2.17 9 65 74 2.1
[HM]
−33.99 2.1
[HM]
−29.49
4 19 M 14484 100 0.7
[20/100]
−4.97 −0.1
[20/16]
−1.45 6 12 18 0.9
[20/160]
−25.77 1
[20/200]
−29.28
5 19 M 11778 97 1.1
[20/250]
−8.86 −0.1
[20/16]
−2.11 9 18 27 2.40
[HM]
−34.62 1.2
[20/320]
−18.94
Mean 27.2 98.63 0.84
[20/125]
−5.15- 0
[20/20]
−1.392 11.4 24.2 35.6 1.82
[CF]
−29.96 1.50
[20/500]
−24.44
Median 26 98.17 0.8
[20/125]
−4.97 0
[20/20]
−1.88 9 15 28 2.1
[HM]
−31.25 1.2
[20/300]
−26.86